Ionis Pharmaceuticals (IONS)
Healthcare · Biotechnology
2 members of Congress have disclosed 2 trades in Ionis Pharmaceuticals (IONS) since 2016: 0 buys and 2 sales. The most recent was disclosed on Apr 17, 2023.
- Trades disclosed
- 2
- Members trading
- 2
- Buys / sells
- 0 / 2
- Reported value
- $2K–$30K
Keep following the company.
Subscribers get new congressional filings and notable insider purchases for companies they follow. Coverage varies by company.
What else is happening at IONS
All research →Company filings and public records connected to this stock, ordered by when they became public or were first observed.
IONS: third_quarter 2026 lobbying report
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
Public: Oct 19, 2026, 7:29 AM EDTOriginal source ↗IONS: third_quarter 2026 lobbying report
Issues related to the implementation of the Inflation Reduction Act. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025. Issues related to drug pricing policy. Issues related to the implementation of the Inflation Reduction Act. H.R.1672 - Maintaining Investments in New Innovation Act. Issues related to the implementation of the Tax Cuts and Jobs Act of 2017. H.R.1414 - Camerons Law.
Public: Oct 15, 2026, 4:28 PM EDTOriginal source ↗IONS: second_quarter 2026 lobbying report
Issues related to the implementation of the Inflation Reduction Act. H.R.1672 - Maintaining Investments in New Innovation Act. Issues related to the implementation of the Tax Cuts and Jobs Act of 2017. H.R.1414 - Camerons Law. Issues related to the implementation of the Inflation Reduction Act. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.1262/S.932 - Give Kids a Chance Act of 2025. Issues related to drug pricing policy.
Public: Jul 17, 2026, 1:48 PM EDTOriginal source ↗IONS: second_quarter 2026 lobbying report
Pediatric Review Reauthorization. H.R.946/S.1862: ORPHAN Cures Act. H.R.1672: Maintaining Investments in New Innovation (MINI) Act. H.R.1262/S.932: Give Kids a Chance Act of 2025.
Public: Jul 5, 2026, 6:00 AM EDTOriginal source ↗
Who traded IONS
- Rep. Daniel S. Goldman (D-NY-10)0 buys · 1 sale01Apr 17, 2023
- Sen. Sheldon Whitehouse (D-RI)0 buys · 1 sale01Feb 23, 2016
All trades
- Apr 17, 2023$1K–$15K
Rep. Daniel S. Goldman (D-NY-10)
Sold Ionis Pharmaceuticals IONS
$1K–$15K · Traded Mar 6, 2023 · disclosed Apr 17, 2023
- Feb 23, 2016$1K–$15K
Sen. Sheldon Whitehouse (D-RI)
Sold (full) Ionis Pharmaceuticals IONS
$1K–$15K · Traded Jan 20, 2016 · disclosed Feb 23, 2016
From periodic transaction reports filed under the STOCK Act. Amounts are the ranges members report, and trades can be disclosed up to 45 days after they happen. Nothing here is investment advice.